Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel
NASDAQ:ZBIO

Zenas BioPharma Q2 2025 Earnings Report

Zenas BioPharma logo
$17.40 +0.27 (+1.58%)
Closing price 04:00 PM Eastern
Extended Trading
$17.35 -0.05 (-0.29%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Zenas BioPharma EPS Results

Actual EPS
-$1.25
Consensus EPS
-$1.02
Beat/Miss
Missed by -$0.23
One Year Ago EPS
N/A

Zenas BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$5.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zenas BioPharma Announcement Details

Quarter
Q2 2025
Date
8/12/2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Zenas BioPharma's Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 12, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Zenas BioPharma's Q2 2025 Press ReleasePress Release
(8-K)
Zenas BioPharma's Q2 2025 Quarterly reportQuarterly report
(10-Q)

Zenas BioPharma Earnings Headlines

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR ...
June 2 at 8:24 PM  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/zenas-biopharma-announces-data-registrational-230500180.html
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
June 2 at 7:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/02/3305741/0/en/zenas-biopharma-announces-data-from-the-registrational-phase-3-indigo-trial-of-obexelimab-in-immunoglobulin-g4-related-disease-igg4-rd-simultaneously-presented-at-the-eular-2026-co.html
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
June 3 at 1:00 AM  |  Weiss Ratings (Ad)
A Look At Zenas BioPharma (ZBIO) Valuation After Strong 1-Year Return And Recent Share Price Weakness
June 1 at 10:29 PM  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/look-zenas-biopharma-zbio-valuation-120654109.html
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
May 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/28/3302683/0/en/zenas-biopharma-announces-submission-of-biologics-license-application-bla-to-u-s-fda-for-obexelimab-in-igg4-rd.html
Zenas Biopharma Inc.
May 26, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/zbio-zenas-biopharma-inc/vitals
See More Zenas BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zenas BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zenas BioPharma and other key companies, straight to your email.

About Zenas BioPharma

Zenas BioPharma (NASDAQ:ZBIO) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies. Its integrated research infrastructure encompasses medicinal chemistry, in vitro and in vivo pharmacology, as well as manufacturing capabilities to support rapid progression of lead molecules into clinical development.

The company’s pipeline includes immuno-oncology candidates designed to modulate checkpoint pathways in solid tumors, alongside antiviral programs targeting broad-spectrum viral threats. Each program is engineered to combine high specificity with favorable pharmacokinetic properties, with key assets currently in IND-enabling stages and early clinical trials.

To advance its programs, Zenas BioPharma collaborates with academic institutions and contract research organizations, leveraging external expertise and resources. Serving global markets, the company is committed to addressing unmet medical needs and bringing differentiated therapies to patients worldwide.

View Zenas BioPharma Profile
Earnings Tools